<div><div>The Vanguard Group, Inc. (IRSH) Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc 31-Dec-2025 / 15:22 GMT/BSTAp27FORM 8.3IRISH TAKEOVER PANELOPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVERRULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE1. KEY INFORMATION<div><table><tbody><tr><td><ul><li>Full name of discloser</li></ul></td><td>The Vanguard Group, Inc.</td></tr><tr><td><ul><li>Owner or controller of interests and short positions disclosed, if different from 1(a) </li></ul>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</td><td></td></tr><tr><td><ul><li>Name of offeror/offeree in relation to whose relevant securities this form relates </li></ul>Use a separate form for each offeror/offeree</td><td>Avadel Pharmaceuticals plc</td></tr><tr><td><ul><li>If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)</li></ul></td><td></td></tr><tr><td><ul><li>Date position held/dealing undertaken </li></ul>For an opening position disclosure, state the latest practicable date prior to the disclosure</td><td>30 December 2025</td></tr><tr><td><ul><li>In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? </li></ul>If it is a cash offer or possible cash offer, state “N/A”</td><td>N/A</td></tr></tbody></table></div>2. INTERESTS AND SHORT POSITIONSIf there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.Ap28Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)(Note 2)<div><table><tbody><tr><td>Class of relevant security (Note 3)</td><td colspan="4">US$0.01 ordinary shares</td></tr><tr><td rowspan="2"></td><td colspan="2">Interests</td><td colspan="2">Short positions</td></tr><tr><td>Number</td><td>%</td><td>Number</td><td>%</td></tr><tr><td><ul><li>Relevant securities owned and/or controlled</li></ul></td><td>5,864,542</td><td>5.97%</td><td></td><td></td></tr><tr><td><ul><li>Cash-settled derivatives</li></ul></td><td></td><td></td><td></td><td></td></tr><tr><td><ul><li>Stock-settled derivatives (including options) and agreements to purchase/ sell</li></ul></td><td></td><td></td><td></td><td></td></tr><tr><td>Total</td><td>5,864,542</td><td>5.97%</td><td></td><td></td></tr></tbody></table></div>All interests and all short positions should be disclosed.Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.The currency of all prices and other monetary amounts should be stated.(a) Purchases and sales<div><table><tbody><tr><td>Class of relevant security</td><td>Purchase/sale</td><td>Number of securities</td><td>Price per unit(Note 5)</td></tr><tr><td>US$0.01 ordinary shares</td><td>Purchase</td><td>610</td><td>21.54 USD</td></tr><tr><td>US$0.01 ordinary shares</td><td>Sale</td><td>306</td><td>21.54 USD</td></tr></tbody></table></div>Ap29(b) Cash-settled derivative transactions<ul><li>Class ofrelevantsecurity</li><li>Product description e.g. CFD</li><li>Nature of dealinge.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position</li><li>Number ofreference securities (Note 6)</li><li>Price per unit (Note 5)</li></ul>(c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying<ul><li>Class of relevant security</li><li>Product description e.g. call option</li><li>Writing, purchasing, selling, varying etc.</li><li>Number of securities to which option relates (Note 6)</li><li>Exerciseprice per unit</li><li>Type e.g. American, Europeanetc.</li><li>Expiry date</li><li>Option moneypaid/ received per unit</li></ul>(ii) Exercise<ul><li>Class of relevant security</li><li>Product description e.g. call option</li><li>Exercising/ exercised against</li><li>Number of securities</li><li>Exercise price per unit (Note 5)</li></ul>(d) Other dealings (including transactions in respect of new securities) (Note 3)<div><table><tbody><tr><td>Class of relevant security</td><td> Not Applicable</td></tr><tr><td>Nature of dealing e.g. subscription, conversion, exercise</td><td></td></tr><tr><td>Details</td><td></td></tr><tr><td>Price per unit (if applicable) (Note 5)</td><td></td></tr></tbody></table></div>Ap304. OTHER INFORMATION(a) Indemnity and other dealing arrangements<ul><li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”</li><li>none</li></ul>(b) Agreements, arrangements or understandings relating to options or derivatives<ul><li>Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.</li><li>none</li></ul>(c) Attachments<ul><li>Is a Supplemental Form 8 attached?</li><li>No</li></ul><div><table><tbody><tr><td>Date of disclosure</td><td>31 December 2025</td></tr><tr><td>Contact name</td><td>Shawn Acker</td></tr><tr><td>Telephone number</td><td>001-610-669-6713</td></tr></tbody></table></div>Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service. Dissemination of a Regulatory Announcement, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.<div><table><tbody><tr><td>Category Code:</td><td>RET - Avadel Pharmaceuticals plc</td></tr><tr><td>TIDM:</td><td>IRSH</td></tr><tr><td>LEI Code:</td><td>5493002789CX3L0CJP65</td></tr><tr><td>Sequence No.:</td><td>413342</td></tr><tr><td>EQS News ID:</td><td>2253326</td></tr></tbody></table></div><div><table><tbody><tr><td colspan="2"> </td></tr><tr><td>End of Announcement</td><td>EQS News Service</td></tr></tbody></table></div> <section>Disclaimer<div>Saving the news in databases or any forwarding of the news to third parties in a commercial context or for commercial purposes is only permitted with the prior written consent of EQS Group AG.</div></section></div></div>

AVDL

The Vanguard Group, Inc. disclosed its position regarding Avadel Pharmaceuticals plc in accordance with the Irish Takeover Panel rules. As of December 30, 2025, Vanguard holds 5,864,542 ordinary shares, representing 5.97% of the company. Recent dealings include the purchase of 610 shares and the sale of 306 shares, both at a price of $21.54 per share. The disclosure was made on December 31, 2025, and no additional agreements or arrangements were reported.